A Randomized Trial of Genotype-Guided Dosing of Warfarin
Why the study?
Does genotype-guided dosing of warfarin improve the percentage of time in the therapeutic INR range in patients initiating warfarin therapy?
Population
Patients initiating warfarin therapy
Comparison
Genotype-guided dosing of warfarin vs Standard dosing of warfarin
Design
RCT, Randomized
Follow-up
During the initiation of warfarin therapy
Authors
Discussion
Loading...
Member takes
Implication
Supports genotype-guided warfarin dosing at initiation; confirms RCT benefit for TTR over standard dosing.
Key Points
- To determine whether pharmacogenetic-based dosing improves anticoagulation control compared to standard dosing during the initiation of warfarin therapy.
- Randomized clinical trial comparing genotype-guided warfarin dosing against standard dosing regimens (ClinicalTrials.gov number, NCT01119300).
- Assessed percentage of time spent within the therapeutic international normalized ratio (INR) range during the initiation phase of therapy.
- Pharmacogenetic-based dosing achieved a higher percentage of time in the therapeutic INR range compared to standard dosing during warfarin initiation.
Structured PICO
Does genotype-guided dosing of warfarin improve the percentage of time in the therapeutic INR range in patients initiating warfarin therapy?
P
Population
Patients initiating warfarin therapy
I
Intervention
Genotype-guided (pharmacogenetic-based) dosing of warfarin
C
Comparator
Standard dosing of warfarin
O
Outcome
Percentage of time in the therapeutic INR rangesurrogate
Genotype-guided dosing of warfarin improves the time in therapeutic INR range during therapy initiation compared to standard dosing.
Cite This Study
Pirmohamed et al. (2013) studied this question.